绥美凯服用说明

It is a compound preparation. Each tablet contains 50 mg of dolutegravir sodium (calculated as dolutegravir), 600 mg of abacavir sulfate (calculated as abacavir) and 300 mg of lamivudine. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). On January 22, 2018, it was officially launched in mainland China. Today we will learn about the instructions for taking Suimeikai.

Dosage and method of taking Suimeikai:

1. Adults and adolescents (weight at least 40 kg)

2. For adults and adolescents, the recommended dosage of this product is one tablet, once a day. 

3. If adults or adolescents weigh less than 40 kg, this product should not be given because this product is a fixed-dose tablet and the dose cannot be reduced. 

4. Suimeikai is a fixed-dose tablet and cannot be used for patients who require dose adjustment. If discontinuation or dose adjustment of one of the active ingredients is necessary, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these drugs. 

5. If the patient misses a dose of Suimeikan and there are more than 4 hours before the next dose, he should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

6. In patients aged ≥65 years, there are limited data on the use of dolutegravir, abacavir and lamivudine. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Suimika in this age group.

Trimax is currently the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

The above is the content of the dosage instructions, I hope it can help you!